FDA Clearance Tracker · P100018-S011
PIPELINE EMBOLIZATION DEVICES,PIPELINE FLEX EMBOLIZATION DEVICE
Last checked: Nov 20, 2026Latest source record: Jan 26, 2015 (this decision)Source: openFDAMethods & limitations
Decided
Jan 26, 2015
Approved
Time to decision
214 days
Received Jun 26, 2014. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P100018-S011
- Device name
- PIPELINE EMBOLIZATION DEVICES,PIPELINE FLEX EMBOLIZATION DEVICE
- Applicant location
- Irvine, CA
- Received
- Jun 26, 2014
- Decided
- Jan 26, 2015
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P100018
Device type
- Device type
- Intracranial aneurysm flow diverter (OUT)
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
APPROVAL FOR DESIGN CHANGES TO THE DELIVERY SYSTEM OF THE PIPELINE¿ EMBOLIZATION SYSTEM. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME, PIPELINE¿ FLEX EMBOLIZATION DEVICE (PFED), AND REMAINS INDICATED FOR THE ENDOVASCULAR TREATMENT OF ADULTS (22 YEARS OF AGE OR OLDER) WITH LARGE OR GIANT WIDE-NECKED INTRACRANIAL ANEURYSMS (IAS) IN THE INTERNAL CAROTID ARTERY FROM THE PETROUS TO THE SUPERIOR HYPOPHYSEAL SEGMENTS.
Source documents
Other decisions for Micro Therapeutics, Inc. d/b/a ev3 Neurovascular
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K241388 · Decided Jan 2, 2025 · 232 days after receipt
Device type: Catheter, Percutaneous, Neurovasculature (QJP) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.